Ivan Kairatov is a Biopharma expert with deep knowledge of technology and innovation in the industry, with experience in research and development. Today, we discuss the recent FDA approval of adaptive deep brain stimulation (aDBS) as a new treatment option for Parkinson’s disease. Can you explain w
Mirum Pharmaceuticals recently made headlines as they secured FDA approval for Ctexli, also known as chenodiol, as the first treatment for cerebrotendinous xanthomatosis (CTX). CTX, a rare genetic lipid storage disease, affects an estimated 3 to 5 individuals per 100,000. This approval came after a
Human aging is a complex process influenced by a combination of genetic and environmental factors. While the role of genetics has been widely studied, recent research highlights the significant impact of environmental exposures on aging and premature mortality. This article delves into the findings
The intersection of biotechnology and artificial intelligence (AI) is poised to address the inefficiencies and ethical concerns plaguing the current drug development process. One of the most promising innovations in this field is the Bio-AI clinical prediction platform developed by Quris-AI, which
In recent developments, a collaborative research team led by the University of Arizona College of Medicine – Tucson has discovered groundbreaking potential for an FDA-approved osteoporosis drug in the treatment of a rare genetic heart disease. The heart condition in question is dilated c
Imagine unlocking a code that holds the secret to the myriad complexities of brain evolution and the onset of neurological diseases. This concept has come closer to reality with a pivotal study led by a Belgian research team, which delves deep into the genetic regulatory codes that control brain
Cancer metastasis remains one of the most challenging aspects of cancer treatment, significantly impacting patient survival rates. Recent research has shed light on the crucial role of the extracellular matrix (ECM) in influencing cancer cell behavior and metastasis. Understanding these
Chordoma, a rare bone cancer affecting about one in a million people, has long been a medical enigma. Historically, the lack of understanding and effective treatments has rendered it untreatable. However, recent breakthroughs by Professor Paul Workman and his team offer new hope. This article
Sangamo Therapeutics, Inc., a leading genomic medicine company, has reported promising updated data from the Phase 1/2 STAAR study. This study explores the efficacy of isaralgagene civaparvovec (ST-920) as a treatment for Fabry disease. The analysis, which reflects data up to September 12, 2024,
The Contract Development and Manufacturing Organization (CDMO) sector is navigating a landscape marked by significant changes and evolving trends. Gil Roth, President of the Pharma & Biopharma Outsourcing Association, provides a comprehensive analysis of the sector's current state and
